From professional translators, enterprises, web pages and freely available translation repositories.
myelosuppression
kaulu smadzeņu nomākums
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
myelosuppression/neutropenia
mielosupresija/neitropēnija
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
myelosuppression was generally
mielosupresija parasti ir atgriezeniska un kontrolējama, dasatinibu uz laiku atceļot vai samazinot devu (skatīt apakšpunktu 4. 2 un 4. 8).
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
myelosuppression is thus common.
tādējādi mielosupresija ir sastopama bieži.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
severe myelosuppression may occur.
var rasties smaga mielosupresija.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
basiliximab does not cause myelosuppression.
baziliksimabs neizraisa mielosupresiju.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
infections and malignancies causing myelosuppression
infekcijas un ļaundabīgi procesi, kas izraisa mielosupresiju
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
therapy with myocet causes myelosuppression.
terapija ar myocet izraisa mielosupresiju.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
management of myelosuppression and associated complications
kaulu smadzeņu nomākuma un ar to saistīto komplikāciju ārstēšana
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
all patients experienced a profound myelosuppression.
visiem pacientiem novērota pilnīga mielosupresija.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
severe myelosuppression (see section 4.4).
smags kaulu smadzeņu nomākums (skatīt 4.4. apakšpunktu).
Last Update: 2017-04-26
Usage Frequency: 14
Quality:
myelosuppression is usually the dose-limiting toxicity.
kaulu smadzeņu nomākums parasti ir devu ierobežojoša toksicitāte.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
myelosuppression (including anaemia, neutropaenia, thrombocytopaenia)
mielosupresija (tai skaitā anēmija, neitropēnija un trombocitopēnija)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
myelosuppression was commonly reported in all patient populations.
visās pacientu populācijās bieži ziņoja par mielosupresiju.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
severe renal or hepatic failure and severe myelosuppression
smaga nieru vai aknu mazspēja un smaga mielosupresija
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
associated with delayed myelosuppression e. g., nitrosoureas. tn uc
rē pierādījumu par šādas mijiedarbības kaitīgumu.
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
myelosuppression may lead to neutropenia and an increased risk of infection.
mielosupresija var izraisīt neitropēniju un paaugstināt infekcijas risku.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
persistent severe myelosuppression, may result in superinfection or haemorrhage.
ilgstošs smags kaulu smadzeņu nomākums var izraisīt superinfekciju vai asiņošanu.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
recovery from myelosuppression is usually rapid when therapy is discontinued.
atveseļošanās kaulu smadzeņu nomākuma gadījumā parasti ir strauja, tiklīdz tiek pārtraukta terapija.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
haematopoietic growth factor has been used in patients with resistant myelosuppression.
hematopoētisko augšanas faktoru lietoja pacientiem ar rezistentu mielosupresiju.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: